---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-005378"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T01:26:05.517589+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeOnc Technologies executes sub-license for NEO100/NEO212 in MENA, milestone toward $50M Quazar deal

## Summary
- NeOnc executed sub-license agreement with its Abu Dhabi subsidiary NuroCure for NEO100 and NEO212, covering UAE, GCC, and MENA.
- This is the second of five conditions to close a $50M strategic investment from Quazar Investment at $25 per share.
- Proposed structure: 70% of proceeds for NeOnc common stock, 30% for clinical trials and infrastructure in MENA.
- Remaining conditions to be satisfied within 120 days, including legal formation of NuroMENA/NuroCure and finalizing offering documents.
- Management also highlighted recent Russell Microcap Index inclusion as part of its capital markets strategy.

## SEC filing metadata
- accession: 0001829126-25-005378
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912625005378/0001829126-25-005378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912625005378/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-005378
- JSON: https://secwatch.observer/filing/0001829126-25-005378.json
- Plain text: https://secwatch.observer/filing/0001829126-25-005378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.